Multimodality Therapy Makes Waves in Bladder Cancer

Welcome to OncLive On Air^™! I’m your host today, Caroline Seymour.

OncLive On Air^™ is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with the faculty of a recent Institutional Perspectives in Cancer webinar on bladder cancer hosted by Cleveland Clinic.

At the meeting, faculty shared updates in the management of metastatic urothelial carcinoma as well as robotic cystectomy and bladder preservation approaches in muscle-invasive bladder cancer.

First, we spoke with the chair of the meeting, Shilpa Gupta, MD, a medical oncologist in the Department of Hematology and Medical Oncology at Cleveland Clinic. Listen on to hear Gupta discuss the research that has been done with immunotherapy in metastatic bladder cancer.

We were then joined by Omar Mian, MD, PhD, staff in Translational Hematology and Oncology Research and staff physician in the Department of Radiation Oncology at Cleveland Clinic. Listen on to hear Mian discuss the optimization of multimodality therapy for bladder preservation.

We closed out the night with Byron Lee, MD, PhD, a surgeon and scientist in the Department of Urology at Glickman Urological and Kidney Institute at Cleveland Clinic, and joint staff in the Department of Cellular and Molecular Medicine at Lerner Research Institute at Cleveland Clinic. Listen on to hear Lee discuss the evolution of surgery in muscle-invasive bladder cancer.